盐酸卡林多 | 729610-18-8

• 物质功能分类: 生物化工 - 生化试剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 盐酸卡林多
• 英文名称: Calindol hydrochloride
• 英文别名: (R)-N-[(indole-2-yl)methyl]-N-[1-(1-naphthyl)ethyl]amine.HCl；(1R)-N-(1H-indol-2-ylmethyl)-1-naphthalen-1-ylethanamine;hydrochloride
• CAS: 729610-18-8
• 化学式: C₂₁H₂₀N₂*ClH
• 分子量: 336.864
• InChiKey: KFILKQPBQZIRST-XFULWGLBSA-N

物化性质

• 熔点：
  208-210?C (dec.)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  5.59
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  27.8
• 氢给体数：
  3
• 氢受体数：
  1

文献信息

• Novel calcium receptor active molecules and method for preparing same
  申请人：——

  公开号：US20030199497A1

  公开（公告）日：2003-10-23

  The invention concerns compounds of general formula (I) wherein: 1 the group X represents a —NR4, —CH═N or —CHR5-NR4-group; the group Y represents an oxygen or sulphur atom or a NR, —CR5, —CHR5-, —CR5=CR6- or —CHR5-CHR6 group provided that when group X represents the —CH═N— or —CHR5-NR4-group, group Y represents an oxygen or a sulphur atom or a Nr, —CR5 or —CHR group; the group R represents a hydrogen atom or an alkyl, aryl or aralkyl group; the groups R1, R5 and R6, identical or different, represent each a hydrogen or halogen atom or an alkyl or alkoxy group; the group R2 represents a hydrogen atom or an alkyl group; the group R3 represents an aryl group; and the group R4 represents a hydrogen atom, an alkyl, aryl, aralkyl, alkylsulphonamide, arylsulphonamide or aralkyl sulphonamide group; and their salt with a pharmaceutically acceptable acid, in the form of a racemic mixture and their optically pure isomer. The invention also concerns their preparation, pharmaceutical compositions containing them and their use as CaSR activity modulator and as medicine for preferably treating diseases or physiological disorders involving the intervention of CaSR activity modulation.

  本发明涉及一般式（I）的化合物，其中：1.基团X代表- NR4，-CH═N或-CHR5-NR4基团；基团Y代表氧或硫原子或NR，-CR5，-CHR5-，-CR5=CR6-或-CHR5-CHR6基团，但当基团X表示-CH═N-或-CHR5-NR4基团时，基团Y代表氧或硫原子或NR，-CR5或-CHR基团；基团R代表氢原子或烷基，芳基或芳烷基；基团R1，R5和R6，相同或不同，分别代表氢或卤原子或烷基或烷氧基；基团R2代表氢原子或烷基；基团R3代表芳基；基团R4代表氢原子，烷基，芳基，芳烷基，烷基磺酰胺，芳基磺酰胺或芳烷基磺酰胺基团；以及它们在药学上可接受的酸盐形式，以外消旋混合物和其光学纯异构体。本发明还涉及它们的制备，含有它们的药物组合物以及它们作为CaSR活性调节剂和作为治疗涉及CaSR活性调节干预的疾病或生理紊乱的药物的用途。
• COMPOSES POSSEDANT UNE ACTIVITE CALCIMIMETIQUE
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：EP1284963B1

  公开（公告）日：2012-05-09
• MATERIALS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
  申请人：UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

  公开号：US20180153826A1

  公开（公告）日：2018-06-07

  In preferred embodiments, the invention pertains to the treatment of Cystic Fibrosis (CF) using an agonistic of CaSR. In a specific embodiment, the subject invention provides a method of treating CF in a subject by administering to the subject a composition comprising a calcimimetic. The calcimimetic can be administered alone or in combination with a CaSR orthosteric agonist and/or an agent capable of stimulating colonic HCO 3− secretion in CFTR-independent manner. The composition can be administered to the subject via inhalation. Accordingly, the invention further pertains to compositions comprising a calcimimetic and optionally, further comprising a CaSR orthosteric agonist and/or an agent capable of stimulating colonic HCO 3− secretion in CFTR-independent manner, in the form suitable for administration to the subject via inhalation. Accordingly, devices for administering the compositions of the current invention via inhalation are also provided.
• US7084167B2
  申请人：——

  公开号：US7084167B2

  公开（公告）日：2006-08-01